With approvals of novel cell and gene therapy products by the FDA anticipated to reach double figures in 2024—following eight US approvals in 2023—advancements in cell and gene therapy (CGT) products are paving the way for early-stage program developers. Now more than ever, it is critical to consider the end-product from the very beginning, establishing a scalable and robust process, and identifying opportunities to streamline without compromising on quality. 

In this roundtable webinar, our expert panelists from across the CGT space will discuss a concept-to-cure program pathway, sharing insights and exploring challenges from a development, manufacturing, and testing perspective. Among the key audience takeaways will be:

• Key differences between material requirements for research vs. GMP vectors
• The importance of standardizing materials and manufacturing processes
• Real-world examples of how the pathway to the clinic can be streamlined

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.